What's in Capricor Inc.'s pipeline?

Capricor Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Capricor Inc.'s portfolio?

Top competitors by shared drug class: Aivita Biomedical, Inc., Bone Therapeutics S.A, Gamida Cell ltd, University of Missouri-Columbia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/capricor-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Capricor Inc. — Portfolio Competitive Intelligence Brief

Capricor Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Deramiocel (CAP-1002)	Deramiocel (CAP-1002)	phase 3	Allogeneic cell therapy		Cardiovascular

Therapeutic area mix

Cardiovascular · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aivita Biomedical, Inc. · 1 shared drug class
Bone Therapeutics S.A · 1 shared drug class
Gamida Cell ltd · 1 shared drug class
University of Missouri-Columbia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Capricor Inc.:

Cite this brief

Drug Landscape (2026). Capricor Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/capricor-inc. Accessed 2026-05-14.